Clinical Trials Logo

Serotonin Syndrome clinical trials

View clinical trials related to Serotonin Syndrome.

Filter by:

NCT ID: NCT00955604 Completed - Serotonin Syndrome Clinical Trials

Azilect + Antidepressant Chart Review

STACCATO
Start date: July 2009
Phase: N/A
Study type: Observational

To identify the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline without antidepressant medications and compared to PD patients receiving antidepressants, but not rasagiline.

NCT ID: NCT00853047 Completed - Carcinoid Syndrome Clinical Trials

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide therapy. Following determination of the maximally tolerated or effective dose, cohort expansion will occur to confirm effect on symptoms and safety profile.

NCT ID: NCT00774930 Completed - Carcinoid Syndrome Clinical Trials

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

ELECT
Start date: May 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in subjects with carcinoid syndrome.

NCT ID: NCT00412061 Completed - Carcinoid Tumor Clinical Trials

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

RADIANT-2
Start date: December 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.